par Lauletta, Antonio;De Le Hoye, Laurène 
;Leonard-Louis, Sarah;Garibaldi, Matteo;Allenbach, Yves;Benveniste, Olivier
Référence Journal of neurology, 272, 8, page (505)
Publication Publié, 2025-07-01
;Leonard-Louis, Sarah;Garibaldi, Matteo;Allenbach, Yves;Benveniste, OlivierRéférence Journal of neurology, 272, 8, page (505)
Publication Publié, 2025-07-01
Article révisé par les pairs
| Résumé : | In the original version of this article, first column of Table 1 was not aligned properly and correct Table 1 should have been The original article has been corrected. Demographic and clinical characteristics, laboratory and histologic data of GM patients compared with IBM controls GM (N=14) GM-IBM (N=8) IBM (controls) (N=18) p-value GM vs GM-IBM (p-value) GM-IBM vs IBM (p-value) Age at GM diagnosis Median [Min, Max] 45.5 [27–77] 53 [35–77] - 0.356 0.356 - Age at IBM diagnosis Median [Min, Max] - 54.5 [42–80] 61 [44–77] 0.342 - 0.342 Sex (F) 7 (50.0%) 2 (25.0%) 10 (55.6%) 0.345 0.486 0.309 Myalgia 9 (64.3%) 5 (62.5%) 5 (27.8%) 0.0776 1 0.214 Clinical involvement at onset Only distal weakness 0 (0%) 1 (12.5%) 0 (0%) 0.129 0.772 0.671 Only proximal weakness 0 (0%) 1 (12.5%) 0 (0%) 0.129 0.772 0.671 Proximodistal weakness 7 (50.0%) 6 (75.0%) 18 (100%) 0.0035* 0.486 0.158 Only myalgia 7 (50.0%) 0 (0%) 0 (0%) <0.001* 0.052 0.0499* Finger flexors weakness 1 (7.1%) 4 (50.0%) 17 (94.4%) <0.001* 0.0753 0.0344* Quadriceps weakness 7 (50.0%) 4 (50.0%) 15 (83.3%) 0.0891 1 0.197 Symmetric involvement 9 (64.3%) 0 (0%) 1 (5.6%) <0.001* 0.0124* 1 Dysphagia 2 (14.3%) 5 (62.5%) 11 (61.1%) 0.0165* 0.0629 1 Sarcoidosis involvement Lung 7 (50.0%) 6 (75.0%) - - 0.380 - Lymph nodes 7 (50.0%) 5 (62.5%) - - 0.675 - Liver/spleen 2 (14.3%) 1 (12.5%) - - 1 - Eye 1 (7.1%) 0 (0%) - - 1 - Skin 4 (28.6%) 1 (12.5%) - - 0.613 - Heart 3 (21.4%) 2 (25.0%) - - 1 - Kidney 1 (7.1%) 0 (0%) - - 1 - CNS 0 (0%) 2 (25.0%) - - 0.121 - Hypercalcemia 1 (7.1%) 3 (37.5%) - - 0.117 - Increased ACE 6 (42.9%) 1 (12.5%) - - 0.193 - CPK (at peak, U/L) Median [Min, Max] 328 [68–3200] 430 [230–2700] 706 [60–1500] 0.388 0.538 0.278 Abnormal lower limb muscle MRI HyperT2 9/13 (69.2%) 5/6 (83.3%) 9/14 (64.3%) 0.696 1 0.613 Thigh 5 (55.5%) 5 (100%) 8 (88.8%) 0.095 0.221 1 -Anterior compartment predominant 2 (40%) 5 (100%) 5 (62.5%) 0.125 0.167 0.231 -Diffuse (ant + post) 3 (60%) 0 (0%) 3 (37.5%) 0.125 0.167 0.231 Leg 5 (55.5%) 1 (20%) 7 (77.8%) 0.112 0.301 0.091 -Posterior compartment predominant 4 (80%) 0 (0%) 5 (71.4%) 0.018* 0.048* 0.028* -Diffuse (ant + post) 1 (20%) 1 (100%) 2 (28.6%) 0.281 0.333 0.375 Fat replacement 5/13 (38.5%) 5/6 (83.3%) 13/14 (85.7%) 0.006* 0.141 0.521 Thigh 4 (80%) 5 (100%) 12 (92.3%) 0.523 1 1 -Anterior compartment predominant 0 (0%) ** 2 (40%) 7 (58.3%) 0.083 0.444 0.620 -Diffuse (ant + post) 1 (20%) 2 (40%) 5 (41.6%) 0.686 1 1 Leg 2 (40%) 2 (40%) 9 (69.2%) 0.374 1 0.326 -Posterior compartment predominant 1 (50%) 0 (0%) 8 (88.8%) 0.039* 1 0.003* -Diffuse (ant + post) 1 (50%) 2 (100%) 1 (11.1%) 0.039* 1 0.055 Muscle biopsy Fiber necrosis 10 (71.4%) 4 (50.0%) 11 (61.1%) 0.599 0.586 0.921 Fiber atrophy 7 (50.0%) 6 (75.0%) 17 (94.4%) 0.0158* 0.486 0.443 Endomysial inflammatory infiltrate 9 (64.3%) 7 (87.5%) 18 (100%) 0.019* 0.497 0.671 Rimmed vacuoles 1 (7.1%) 7 (87.5%) 17 (94.4%) <0.001* <0.001* 1 MHC-I upregulation 9 (64.3%) 7 (87.5%) 18 (100%) 0.019* 0.497 0.671 COX-negative fibers 0 (0%) 2 (25.0%) 11 (61.1%) 0.0011* 0.234 0.202 C5b-9 deposition Sarcolemmal 2 (14.3%) 1 (12.5%) 1 (5.6%) 0.692 1 0.529 Endomysial capillaries 1 (7.1%) 0 (0%) 0 (0%) 1 1 1 Both 0 (0%) 1 (12.5%) 0 (0%) 0.129 0.176 0.126 GM Granulomatous myositis, IBM inclusion body myositis, CPK Creatine phosphokinase, MHC-I major histocompatibility complex, COX Cytochrome c oxidase, CNS central nervous system, ACE angiotensin-converting enzyme GM group includes GM-sarcoidosis, Isolated GM, and GM-Crohn. The GM-IBM group includes GM-Sarcoidosis and Isolated GM groups that developed IBM *Statistically significant **Posterior predominant muscle involvement in 3 cases |
